ARISTOTLE LABORATORIES
Refounding Medicine
VISION
Eroom’s Law teaches us medicine as a technological enterprise is broken. We are getting worse at inventing new therapies, not better. Aristotle Laboratories aims to fix this by giving the engine a complete overhaul. We replace monotherapy dogma with a multi-modal systems approach, build delivery strategy into our therapeutic design rather than treating it as a secondary consideration, jettison animal experiments in favor of direct-to-human opportunities, embrace clinical trial innovation including serial n=1 experiments, attack rare dise and bind it all together with custom AIs equipped with massive quantities of relevant knowledge and propriety hardware that allows for real-time AI engagement with patients for both intervention and data-collection. Other companies have tried certain of these strategies. We believe putting medicine on an exponential trajectory requires integrating them all.
​
TEAM
Phil Murray and Andrew Mitchell met as colleagues at a Boston-based venture firm. Observing firsthand the agonizingly slow pace of even the most innovative companies in health, they grew disillusioned. Each left to pursue other projects. However, they never gave up on accelerating physiological technology. Their conversations kept returning to the question of how they might do better. Aristotle is the product of those conversations.
Phil serves as CEO. He has operating experience at multiple biotech startups and is a co-inventor of the combination therapy marketed under the trade name Cobenfy. He holds a BS in mechanical engineering from MIT.
​
Andrew serves as CTO. He is a multi-industry entrepreneur with experience in non-dilutive fundraising. He holds a PhD in biochemistry from Harvard University and a BA in philosophy from Cornell University.
​
